 The purpose of this study is to describe the immunogenicity and safety of Sanofi Pasteurs DTaP-IPV-Hep B-PRP-T fully liquid combined hexavalent vaccine Hexaxim administered at 2, 3, and 4 months of age and at 16 to 17 months of age in infants and toddlers who received a dose of Hep B vaccine at birth or within 1 week after birth. 